{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}],"title":"Complete response"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}],"title":"Partial response"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"3"}],"title":"Progressive disease"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"3"}],"title":"Stable disease"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}],"title":"Not evaluable"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"0"}],"title":"Not assessed for response"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"15"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"6"}],"units":"Participants"}],"description":"Objective response rate was defined as the proportion of subjects who achieved a best disease response of either Complete or Partial (CR or PR) based on the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed generally by MRI, CT, or PET-CT and are summarized as: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions. Participants who discontinued study therapy due to clinical progression, radiographic progression, or death without the required tumor assessments were considered to be non-responders in the Objective Response Rate (ORR) calculation. The efficacy analysis included all subjects with baseline tumor measurements who received at least 1 dose of study drug.","groups":[{"description":"Participants received pembrolizumab 200 mg IV every 3 weeks in combination with PLX3397 at 400 mg/day (administered twice daily \\[BID\\] as a split dose of 200 mg in the morning and 200 mg in the evening).","id":"OG000","title":"Dose Escalation: 400 mg/Day"},{"description":"Participants received pembrolizumab 200 mg IV every 3 weeks in combination with PLX3397 at 600 mg/day (administered twice daily \\[BID\\] as a split dose of 200 mg in the morning and 400 mg in the evening).","id":"OG001","title":"Dose Escalation: 600 mg/Day"},{"description":"Participants with liver metastases received pembrolizumab 200 mg IV every 3 weeks in combination with PLX3397 at 600 mg/day (administered twice daily \\[BID\\] as a split dose of 200 mg in the morning and 400 mg in the evening).","id":"OG002","title":"Dose Escalation: 600 mg/Day (Liver Metastases"},{"description":"Participants with no liver metastases received pembrolizumab 200 mg IV every 3 weeks in combination with PLX3397 at 600 mg/day (administered twice daily \\[BID\\] as a split dose of 200 mg in the morning and 400 mg in the evening).","id":"OG003","title":"Dose Escalation: 600 mg/Day (no Liver Metastases)"},{"description":"Participants with liver metastases received pembrolizumab 200 mg IV every 3 weeks in combination with of PLX3397 at 800 mg/day (administered twice daily \\[BID\\] as a split dose of 400 mg in the morning and 400 mg in the evening).","id":"OG004","title":"Dose Escalation: 800 mg/Day (Liver Metastases)"},{"description":"Participants with no liver metastases received pembrolizumab 200 mg IV every 3 weeks in combination with of PLX3397 at 800 mg/day (administered twice daily \\[BID\\] as a split dose of 400 mg in the morning and 400 mg in the evening).","id":"OG005","title":"Dose Escalation: 800 mg/Day (no Liver Metastases)"},{"description":"Participants with melanoma received pembrolizumab 200 mg IV every 3 weeks in combination with PLX3397 at 600 mg/day (administered twice daily \\[BID\\] as a split dose of 200 mg in the morning and 400 mg in the evening).","id":"OG006","title":"Dose Expansion: Melanoma"},{"description":"Participants with NSCLC received pembrolizumab 200 mg IV every 3 weeks in combination with PLX3397 at 600 mg/day (administered twice daily \\[BID\\] as a split dose of 200 mg in the morning and 400 mg in the evening).","id":"OG007","title":"Dose Expansion: NSCLC"},{"description":"Participants with ovarian cancer received pembrolizumab 200 mg IV every 3 weeks in combination with PLX3397 at 600 mg/day (administered twice daily \\[BID\\] as a split dose of 200 mg in the morning and 400 mg in the evening).","id":"OG008","title":"Dose Expansion: Ovarian Cancer"},{"description":"Participants with SCCHN received pembrolizumab 200 mg IV every 3 weeks in combination with PLX3397 at 600 mg/day (administered twice daily \\[BID\\] as a split dose of 200 mg in the morning and 400 mg in the evening).","id":"OG009","title":"Dose Expansion: SCCHN"},{"description":"Participants with GIST received pembrolizumab 200 mg IV every 3 weeks in combination with PLX3397 at 600 mg/day (administered twice daily \\[BID\\] as a split dose of 200 mg in the morning and 400 mg in the evening).","id":"OG010","title":"Dose Expansion: GIST"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Overall best response was assessed in the Efficacy Analysis Set.","reportingStatus":"POSTED","timeFrame":"1 year (Dose Escalation); 2 years (Dose Expansion)","title":"Summary of the Percentage of Participants With Objective Response Rate Assessed by RECIST v1.1 During Pembrolizumab and PLX3397","type":"SECONDARY","unitOfMeasure":"Participants"}